Compare · NAGE vs RLX
NAGE vs RLX
Side-by-side comparison of Niagen Bioscience Inc. (NAGE) and RLX Technology Inc. (RLX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NAGE and RLX operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- RLX is the larger of the two at $3.18B, about 12.2x NAGE ($261.2M).
- Over the past year, NAGE is down 66.2% and RLX is down 9.1% - RLX leads by 57.1 points.
- NAGE has hit the wire 11 times in the past 4 weeks while RLX has been quiet.
- RLX has more recent analyst coverage (2 ratings vs 1 for NAGE).
PerformanceNAGE-66.20%RLX-9.09%
2025-07-21+0.00%2026-07-17
- Company
- Niagen Bioscience Inc.
- RLX Technology Inc.
- Price
- $3.27-3.96%
- $2.05+1.23%
- Market cap
- $261.2M
- $3.18B
- 1M return
- -4.94%
- +4.06%
- 1Y return
- -66.20%
- -9.09%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 11
- 0
- Recent ratings
- 1
- 2
RLX
RLX Technology Inc.
RLX Technology Inc., together with its subsidiaries, researchers, develops, manufactures, distributes, and sells e-vapor products in the People's Republic of China. It serves RELX branded partner stores and other retail outlets through distributors. RLX Technology Inc. was founded in 2018 and is based in Beijing, China.
Latest NAGE
- Niagen Bioscience Appoints Abhijit Kale, Ph.D., as Senior Director of Global External Research
- Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)
- SEC Form 424B5 filed by Niagen Bioscience Inc.
- SEC Form EFFECT filed by Niagen Bioscience Inc.
- Niagen Bioscience CEO Rob Fried to Participate in Virtual Fireside Chat to Discuss Pharmaceutical Strategy on July 15, 2026
- SVP, General Counsel Lopez Carlos Luis was granted 2,314 shares, increasing direct ownership by 103% to 4,565 units (SEC Form 4)
- Chief Financial Officer Pamir Ozan was granted 4,255 shares, increasing direct ownership by 58% to 11,627 units (SEC Form 4)
- Chief Executive Officer Fried Robert N was granted 1,106 shares, increasing direct ownership by 0.10% to 1,060,087 units (SEC Form 4)
- Niagen Bioscience Launches Pharmaceutical Program for Accelerated Aging and Rare Genetic Diseases
- Niagen Bioscience Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
Latest RLX
- SEC Form 6-K filed by RLX Technology Inc.
- RLX Technology Announces Unaudited First Quarter 2026 Financial Results
- RLX Technology to Report First Quarter 2026 Financial Results on May 20, 2026
- RLX Technology Files 2025 Annual Report on Form 20-F
- SEC Form 20-F filed by RLX Technology Inc.
- SEC Form 3 filed by new insider Wang Ying Kate
- SEC Form 3 filed by new insider Jiang Long
- SEC Form 3 filed by new insider Xi Youmin
- SEC Form 3 filed by new insider Wen Yilong
- SEC Form 3 filed by new insider Lu Chao